You’ve explored our un-partnered Alzheimer’s assets dashboard and our trends in novel epigenetics dashboard. We’d now like to offer you a look into our immunokinase targets dashboard, in which we profile select immunokinases, focusing on novel metrics in three interactive dashboards. We examined the trends between BTK (Bruton’s Tyrosine Kinase), IRAK4 (interleukin-1 receptor-associated kinase 4), JAK1 (Janus kinase 1), JAK2 (Janus kinase 2), JAK3 (Janus kinase 3), NIK (NF-κB-inducing kinase), NIK beta subunit (NF-κB-inducing kinase subunit Beta), PI3K delta (Phosphatidylinositide 3-kinase delta subunit), SYK (Spleen Tyrosine Kinase), ZAP70 (Zeta-chain-associated protein kinase 70), MYD88 (myeloid differentiation primary response 88), and TYK2 (Non-receptor tyrosine-protein kinase 2). First, we profiled the relative output of research grants, scientific publications, and intellectual property in relation to each target.

Next, we looked at the targets in terms of which targets are “emerging,” meaning they are not well-known but are steadily gaining a presence in research and patents, and which targets are “established,” meaning they are well-known and have a steady, stable presence in research and patents.

Finally, we looked into the pipeline of each drug, pre-clinical or clinical, that targeted one of the selected immunokinases we profiled.